Avalo Therapeutics (NASDAQ: AVTX) revenue
Avalo Therapeutics reported revenue of $0.1m for fiscal 2025, 86.6% less than in fiscal 2024 ($0.4m). Since fiscal 2016 its revenue has fallen by 94.9%, an average decline of 28.1% a year.
Avalo Therapeutics's revenue has fallen for 3 years in a row, and its best year of the last 10 was fiscal 2017. The biggest drop was in fiscal 2023, −89.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.1m | −86.6% | −$72.9m | −123,601.7% |
| 2024 | $0.4m | −77.1% | −$68.5m | −15,535.6% |
| 2023 | $1.9m | −89.3% | −$27.4m | −1,421.6% |
| 2022 | $18.1m | +234.4% | −$37.4m | −207.4% |
| 2021 | $5.4m | −19.4% | −$82.1m | −1,521.6% |
| 2020 | $6.7m | −0.8% | −$72.8m | −1,087.4% |
| 2019 | $6.8m | −4.0% | −$16.1m | −239.1% |
| 2018 | $7.0m | −74.7% | −$35.4m | −503.4% |
| 2017 | $27.8m | +2,312.3% | $13.9m | 49.9% |
| 2016 | $1.2m | — | −$16.1m | −1,394.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Avalo Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Avalo Therapeutics ranks 400th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Avalo Therapeutics, −86.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 398th | Pulse Biosciences | $0.4m | — |
| 399th | Connect Biopharma | $0.1m | −99.8% |
| 400th | Avalo Therapeutics | $0.1m | −86.6% |
| 401st | Altimmune | $0.0m | 105.0% |
| 402nd | Lyell Immunopharma | $0.0m | −41.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Avalo Therapeutics
- How much revenue did Avalo Therapeutics make in fiscal 2025?
- Avalo Therapeutics reported revenue of $0.1m for fiscal 2025, compared with $0.4m in fiscal 2024.
- How much has the revenue of Avalo Therapeutics fallen?
- Between fiscal 2016 and fiscal 2025 it went from $1.2m to $0.1m: 94.9% less, an average decline of 28.1% a year.
- What was the best year for revenue at Avalo Therapeutics?
- Of its last 10 fiscal years, fiscal 2017, with $27.8m.
- Where does Avalo Therapeutics rank in its sector by revenue?
- It ranks 400th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Avalo Therapeutics come from?
- From the annual report (Form 10-K) that Avalo Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Avalo Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Avalo Therapeutics: the Avalo Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.